Abstract

Iron is an essential element in the central nervous system that is involved in many of its important biological processes, such as oxygen transportation, myelin production, and neurotransmitter synthesis. Previous studies have observed the selective accumulation of iron in Aβ aggregates and neurofibrillary tangles in the brains of patients with Alzheimer’s disease, and excess of this accumulation is associated with accelerated cognitive decline in Alzheimer’s patients. Emerging evidence suggests that ferroptosis, cell death due to iron accumulation, is a potential therapeutic target for treating Alzheimer’s disease. Insamgobonhwan (GBH) is a well-regarded traditional medicine from Donguibogam that possess antioxidant properties and has been suggested to slow the aging process. However, the neuroprotective role of GBH against lipid peroxidation-induced ferroptosis and its positive cognitive effects remain unexplored. Here, we investigated the ability of GBH to protect against RSL3-induced ferroptosis in vitro and to suppress amyloid-β-induced cognitive impairment in vivo. First, we treated HT22 cells with RSL3 to induce ferroptosis, which is an inhibitor of glutathione peroxidase 4 (GPX4) and induces lethal lipid hydroperoxide accumulation, reactive oxygen species (ROS) production, and ferroptotic cell death. GBH treatment inhibited cell death and lipid peroxidation, which were increased by RSL3 administration. In addition, GBH restored the expression of ferroptosis marker proteins, such as GPX4, HO-1 and COX-2, which were altered by RSL3. Next, we examined whether the protective ability of GBH in cells was reproduced in animals. We concluded that GBH treatment inhibited Aβ-induced lipid peroxidation and improved Aβ-induced cognitive impairment in mice.

Highlights

  • Alzheimer’s disease, the most common cause of dementia, is characterized by the presence of amyloid-β (Aβ) plaques

  • Ferroptosis is characterized by mitochondrial reduction and lipid peroxidation, which can be triggered by the inhibition of glutathione peroxidase 4 (GPX4) and by blocking cystine uptake by the system xc, a cystine/glutamate antiporter [3,4]

  • We confirmed the presence of Protodioscin in GBH chemical profile (standard compound retention time (S-rt): 17.21 min/GBH compound retention time (G-rt): 17.34 min), which we chose to act as the representative indication for Asparagus cochinchinensis in GBH [21,22]

Read more

Summary

Introduction

Alzheimer’s disease, the most common cause of dementia, is characterized by the presence of amyloid-β (Aβ) plaques. Iron accumulation in the brain causes ferroptosis, which is a recently discovered form of programmed cell death. Some ferroptosis inhibitors have already shown possible clinical benefits in clinical trials. The metal ion chelating agent deferoxamine and ferroptosis inhibitor ferrostatin-1 may significantly improve the pathology of neurodegenerative diseases in vitro and in vivo [5,6,7,8]. These recent studies provide inspiration to investigate the possibility of targeting ferroptosis in neurodegenerative diseases

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call